Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other ...

(“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2024 financial results and ...

(“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2024 financial results ...

("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2024 financial results and ...

Instil had $115.1 million in total cash, cash equivalents, restricted cash and marketable securities, which consisted ...

Explore Instil Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TIL. Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over ...

ImmuneOnco plans to release clinical data for AXN-2510/IMM2510 in NSCLC in 2025, initiating trials in China and the U.S. Instil Bio, Inc. announced plans for the clinical development of its ...

This compares with -$12.93 million, or -$1.99 per share, last year. Excluding items, Instil Bio, Inc. reported adjusted earnings of -$7.05 million or -$1.08 per share for the period. Instil Bio ...